ELCC 2018 | Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents

Federico Cappuzzo

In this interview, Federico Cappuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of non-small cell lung cancer (NSCLC) from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland. Dr Cappuzzo focuses on immunotherapy and targeted agents, and emphasizes the continued importance of defining the biological characteristics of NSCLC, particularly PD-L1 expression.

Share this video